A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
As an early event in the viral life cycle, the entry of enveloped viruses into target cells has received considerable attention. Viral fusion to cellular targets has been studied principally with fusion assays in which cells engineered to express the viral envelope are cultured with the target cells. These assays yield valuable information but do not fully recapitulate all of the variables governing the fusion of actual virions to their cellular targets. The virion membrane and the plasma membrane, for example, differ strikingly in their lipid and protein compositions. Two virion-based fusion assays have been described. One is based on the redistribution of a self-quenching fluorophore, whereas the second depends on photosensitized activation of a hydrophobic probe by a fluorescent lipid loaded into the target membrane. These assays are complex and have not been adapted to study fusion in complex cell populations. We have developed a simple, rapid assay allowing the detection of HIV-1 virion fusion to biologically relevant target cells, including primary CD4(+) T lymphocytes. It is based on the incorporation of beta-lactamase-Vpr chimeric proteins (BlaM-Vpr) into HIV-1 virions and their subsequent delivery into the cytoplasm of target cells as a result of virion fusion. This transfer is then detected by enzymatic cleavage of the CCF2 dye, a fluorescent substrate of beta-lactamase (BlaM), loaded in the target cells. BlaM cleaves the beta-lactam ring in CCF2, changing its fluor…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Nguyen, D. H., & Hildreth, J. E. K. (2000) · Journal of Virology · doi:10.1128/jvi.74.7.3264-3272.2000 · Cited by 788
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5698 · Cited by 751 · cited 1×
“Conversely, no shift to increased blue fluorescence was observed in these CCR5-Jurkat T cells when the culture was preincubated with 250 nM TAK-779, an inhibitor of CCR5-dependent entr”
BackgroundZlokarnik, G., Negulescu, P. A., Knapp, T. E., Mere, L., Burres, N., Feng, L., Whitney, M., Roemer, K., & Tsien, R. Y. (1998) · Science · doi:10.1126/science.279.5347.84 · Cited by 690
Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4
Schols, D., Struyf, S., Damme, J. V., Esté, J. A., Henson, G., & Clercq, E. D. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1383 · Cited by 554 · cited 1×
“Consistent with this color change deriving from the fusion of virions to the target cells, essentially no blue cells were detected in virally infected HeLa-CD4 cells pretreated with 250 nM AMD3100, an inhibitor of CXCR4-dependent viral entr”
BackgroundAloia, R. C., Tian, H., & Jensen, F. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5181 · Cited by 440
Nussbaum, O., Broder, C. C., & Berger, E. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.5411-5422.1994 · Cited by 338
Dynamic Disruptions in Nuclear Envelope Architecture and Integrity Induced by HIV-1 Vpr
de Noronha, C. M. C., Sherman, M. P., Lin, H. W., Cavrois, M. V., Moir, R. D., Goldman, R. D., & Greene, W. C. (2001) · Science · doi:10.1126/science.1063957 · Cited by 276 · cited 1×
“1-BlaM into the Hin dIII site of pCMV4-HA-Vpr (ref”
MethodSelf-citationHIV-1 Actively Replicates in Naive CD4+ T Cells Residing within Human Lymphoid Tissues
Eckstein, D. A., Penn, M. L., Korin, Y. D., Scripture-Adams, D. D., Zack, J. A., Kreisberg, J. F., Roederer, M., Sherman, M. P., Chin, P. S., & Goldsmith, M. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00217-5 · Cited by 232
Bridger, G. J., Skerlj, R. T., Thornton, D., Padmanabhan, S., Martellucci, S. A., Henson, G. W., Abrams, M. J., Yamamoto, N., & Vreese, K. D. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00002a019 · Cited by 209
Cytosolic Gag p24 as an Index of Productive Entry of Human Immunodeficiency Virus Type 1
Maréchal, V., Clavel, F., Heard, J. M., & Schwartz, O. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2208-2212.1998 · Cited by 207 · cited 1×
“However, in the absence of appropriate viral receptors in the vesicles, this entry pathway does not lead to productive infectio”
Background
Cited by
HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes
Miyauchi, K., Kim, Y., Latinovic, O., Morozov, V., & Melikyan, G. B. (2009) · Cell · doi:10.1016/j.cell.2009.02.046 · Cited by 681
“433 HIV-1 Fusion Is Delayed Relative to Its Escape from a Membrane-Impermeant Fusion Inhibitor Virus-cell fusion was directly quantified by measuring the cytosolic activity of viral core-associated b-lactamase (BlaM) ( Cavrois et al., 2002 ).”
Liu, S.-Y., Aliyari, R., Chikere, K., Li, G., Marsden, M. D., Smith, J. K., Pernet, O., Guo, H., Nusbaum, R., Zack, J. A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.11.005 · Cited by 678
“…efficiency of virus-cell fusion can be measured by the increase in the ratio of blue to green (blue:green) fluorescence, which is reflective of the βla activity associated with βlaM that was been released into the cytoplasm after VSV-G mediated fusion (Cavrois et al., 2002; Wolf et al., 2009).”
Backgroundvon Kleist, L., Stahlschmidt, W., Bulut, H., Gromova, K., Puchkov, D., Robertson, M. J., MacGregor, K. A., Tomilin, N., Pechstein, A., Chau, N., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.025 · Cited by 573
Semen-Derived Amyloid Fibrils Drastically Enhance HIV Infection
Münch, J., Rücker, E., Ständker, L., Adermann, K., Goffinet, C., Schindler, M., Wildum, S., Chinnadurai, R., Rajan, D., Specht, A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.014 · Cited by 543
“conducted in principle as described (Cavrois et al., 2002; Goffinet et al., 2007).”
BackgroundMethodSERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef
Usami, Y., Wu, Y., & Göttlinger, H. G. (2015) · Nature · doi:10.1038/nature15400 · Cited by 467
A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
Xia, S., Yan, L., Xu, W., Agrawal, A. S., Algaissi, A., Tseng, C.-T. K., Wang, Q., Du, L., Tan, W., Wilson, I. A., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav4580 · Cited by 501
“HCoV virion–based fusion assay An HCoV virion–based fusion assay was performed, as described elsewhere (34, 35).”
Abortive HIV Infection Mediates CD4 T Cell Depletion and Inflammation in Human Lymphoid Tissue
Doitsh, G., Cavrois, M., Lassen, K. G., Zepeda, O., Yang, Z., Santiago, M. L., Hebbeler, A. M., & Greene, W. C. (2010) · Cell · doi:10.1016/j.cell.2010.11.001 · Cited by 452
“Virion-based fusion assay was performed as previously described (Cavrois et al., 2002).”
InfluentialSelf-citationHIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation
Rosa, A., Chande, A., Ziglio, S., De Sanctis, V., Bertorelli, R., Goh, S. L., McCauley, S. M., Nowosielska, A., Antonarakis, S. E., Luban, J., et al. (2015) · Nature · doi:10.1038/nature15399 · Cited by 453
Antibodies and Genetically Engineered Related Molecules: Production and Purification
Roque, A. C. A., Lowe, C. R., & Taipa, M. A. (2004) · Biotechnology Progress · doi:10.1021/bp030070k · Cited by 360
A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors
Park, R. J., Wang, T., Koundakjian, D., Hultquist, J. F., Lamothe-Molina, P., Monel, B., Schumann, K., Yu, H., Krupzcak, K. M., Garcia-Beltran, W., et al. (2017) · Nature Genetics · doi:10.1038/ng.3741 · Cited by 333
FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection
Johansen, L. M., Brannan, J. M., Delos, S. E., Shoemaker, C. J., Stossel, A., Lear, C., Hoffstrom, B. G., DeWald, L. E., Schornberg, K. L., Scully, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005471 · Cited by 332
“EBOV entry and internalization assays The b-lactamase (BlaM) entry assay (42) was adapted for assessing effects of candidate inhibitory compounds on EBOV VLP entry as follows.”
MethodDesai, T. M., Marin, M., Chin, C. R., Savidis, G., Brass, A. L., & Melikyan, G. B. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004048 · Cited by 326
“Since published data suggest that IFITM3 likely inhibits the viral fusion step, a direct virus-cell fusion assay was employed to evaluate the extent of restriction in different cell lines [23].”
MethodStrategies for in vivo imaging of enzyme activity: an overview and recent advances
Razgulin, A., Ma, N., & Rao, J. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15035a · Cited by 298
Maturation-Dependent HIV-1 Surface Protein Redistribution Revealed by Fluorescence Nanoscopy
Chojnacki, J., Staudt, T., Glass, B., Bingen, P., Engelhardt, J., Anders, M., Schneider, J., Müller, B., Hell, S. W., & Kräusslich, H.-G. (2012) · Science · doi:10.1126/science.1226359 · Cited by 283
“Virus entry into PBMCs was measured by a modified β-lactamase (BlaM) fusion assay (23).”
MicroRNAs are minor constituents of extracellular vesicles that are rarely delivered to target cells
Albanese, M., Chen, Y.-F. A., Hüls, C., Gärtner, K., Tagawa, T., Mejias-Perez, E., Keppler, O. T., Göbel, C., Zeidler, R., Shein, M., et al. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009951 · Cited by 249
Involvement of Clathrin-Mediated Endocytosis in Human Immunodeficiency Virus Type 1 Entry
Daecke, J., Fackler, O. T., Dittmar, M. T., & Kräusslich, H.-G. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1581-1594.2005 · Cited by 239
“Cells were analyzed for the blue fluorescent cleavage product by fluorescence microscopy at a wavelength of 447 nm (a and b) and for the green fluorescent substrate at a wavelength of 520 nm (a and b ) (9, 59).”
BackgroundGuanylate Binding Protein (GBP) 5 Is an Interferon-Inducible Inhibitor of HIV-1 Infectivity
Krapp, C., Hotter, D., Gawanbacht, A., McLaren, P. J., Kluge, S. F., Stürzel, C. M., Mack, K., Reith, E., Engelhart, S., Ciuffi, A., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.02.019 · Cited by 256
A Stiffness Switch in Human Immunodeficiency Virus
Kol, N., Shi, Y., Tsvitov, M., Barlam, D., Shneck, R. Z., Kay, M. S., & Rousso, I. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.093914 · Cited by 249
“To correlate virus mechanical properties and biological activity, we measured the entry activity of virus particles used in this work using a fluorescence-based assay (18).”
Cell-Cell Transmission Enables HIV-1 to Evade Inhibition by Potent CD4bs Directed Antibodies
Abela, I. A., Berlinger, L., Schanz, M., Reynell, L., Günthard, H. F., Rusert, P., & Trkola, A. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002634 · Cited by 229
Toremifene interacts with and destabilizes the Ebola virus glycoprotein
Zhao, Y., Ren, J., Harlos, K., Jones, D. M., Zeltina, A., Bowden, T. A., Padilla-Parra, S., Fry, E. E., & Stuart, D. I. (2016) · Nature · doi:10.1038/nature18615 · Cited by 243
Johansen, L. M., DeWald, L. E., Shoemaker, C. J., Hoffstrom, B. G., Lear-Rooney, C. M., Stossel, A., Nelson, E., Delos, S. E., Simmons, J. A., Grenier, J. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5597 · Cited by 236
“EBOV entry and internalization assays The BlaM entry assay (57) was adapted for assessing effects of candidate inhibitory compounds on EBOV-VLP entry as described in (11, 14).”
MethodIFITM Proteins Incorporated into HIV-1 Virions Impair Viral Fusion and Spread
Compton, A. A., Bruel, T., Porrot, F., Mallet, A., Sachse, M., Euvrard, M., Liang, C., Casartelli, N., & Schwartz, O. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.11.001 · Cited by 231
“(Cavrois et al., 2002; Roesch et al., 2012).”
MethodWyma, D. J., Jiang, J., Shi, J., Zhou, J., Lineberger, J. E., Miller, M. D., & Aiken, C. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3429-3435.2004 · Cited by 223
Loré, K., Smed-Sörensen, A., Vasudevan, J., Mascola, J. R., & Koup, R. A. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042413 · Cited by 209
“Production of p24 in infected T cells represents a late stage of the virus replication cycle and may not reflect the absolute amount of virus that is transferred from DCs to T cells (20).”
BackgroundHIV entry and envelope glycoprotein-mediated fusion
Blumenthal, R., Durell, S., & Viard, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.406272 · Cited by 212
“Another fusion assay was later developed that relies on the co-incorporation within the virus of an enzyme linked to the HIV accessory protein Vpr (59).”
MethodLavillette, D., Pécheur, E.-I., Donot, P., Fresquet, J., Molle, J., Corbau, R., Dreux, M., Penin, F., & Cosset, F.-L. (2007) · Journal of Virology · doi:10.1128/jvi.02642-06 · Cited by 187
“protein R (Vpr) (9) (BlaM-Vpr was kindly provided by W.”
MethodBurt, T. D., Agan, B. K., Marconi, V. C., He, W., Kulkarni, H., Mold, J. E., Cavrois, M., Huang, Y., Mahley, R. W., Dolan, M. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803526105 · Cited by 205
“Measurements of HIV fusion in SupT1-CCR5 cells were performed with the fluorescence resonance energy transfer-based fusion assay, as described (29).”
MethodSelf-citationIFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro
Prelli Bozzo, C., Nchioua, R., Volcic, M., Koepke, L., Krüger, J., Schütz, D., Heller, S., Stürzel, C. M., Kmiec, D., Conzelmann, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24817-y · Cited by 185
Morizono, K., Xie, Y., Olafsen, T., Lee, B., Dasgupta, A., Wu, A. M., & Chen, I. S. Y. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.03.012 · Cited by 206
“290 Cell Host & Microbe 9, 286–298, April 21, 2011 a2011 Elsevier In We further demonstrated entry of virus in the presence of hGas6 using cytoplasmic CCF2 dye and virion-incorporated b-lactamase (Cavrois et al., 2002) (Figure S2A).”
Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm
Melikyan, G. B. (2008) · Retrovirology · doi:10.1186/1742-4690-5-111 · Cited by 186
“Novel techniques monitoring the delivery of viral core-associated enzyme into a host cell permit direct assessment of the extent and kinetics of virus-cell fusion [33-37], but these assays have limited sensitivity and temporal resolution.”
MethodNovel Fluorogenic Substrates for Imaging β-Lactamase Gene Expression
Gao, W., Xing, B., Tsien, R. Y., & Rao, J. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036126o · Cited by 202
Dismuke, D. J., & Aiken, C. (2006) · Journal of Virology · doi:10.1128/jvi.80.8.3712-3720.2006 · Cited by 194
“To determine whether fusion was affected, we assayed this directly using a recently described virus-cell reporter fusion assay (12).”
MethodShan, L., Deng, K., Gao, H., Xing, S., Capoferri, A. A., Durand, C. M., Rabi, S. A., Laird, G. M., Kim, M., Hosmane, N. N., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.014 · Cited by 180
“To test this prediction, we used an enzyme-based assay that specif- Im ically detects viral entry (Cavrois et al., 2002).”
MethodJia, R., Pan, Q., Ding, S., Rong, L., Liu, S.-L., Geng, Y., Qiao, W., & Liang, C. (2012) · Journal of Virology · doi:10.1128/jvi.01828-12 · Cited by 181
“1A): (1-21), 5=-GCACGGATCCATGGATTACAAGGATGACGACGA TAAGATGCTCAAGGAGGAGCACGAG-3= and 5=-GCACGAATTCCT ATCCATAGGCCTGGAAG-3=; (17-20), 5=-CTCTCCTGTCAACAGT GGCCAGGAGATGCTCAAGGAGGAGCAC-3= and 5=-GTGCTCCTCC TTGAGCATCTCCTGGCCACTGTTGACAGGAGAG-3=; 1718, 5=-CC TGTCAACAGTGGCCAGAACTATGAGATGCTCAAG-3= and 5=-CTT GAGCATCTCATAGTTCTGGCC…”
BackgroundCampbell, E. M., Nunez, R., & Hope, T. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5745-5755.2004 · Cited by 177
“productive entry of viral cores into the cytoplasm (10).”
BackgroundMethodRoan, N. R., Münch, J., Arhel, N., Mothes, W., Neidleman, J., Kobayashi, A., Smith-McCune, K., Kirchhoff, F., & Greene, W. C. (2009) · Journal of Virology · doi:10.1128/jvi.01366-08 · Cited by 174
“Next, the effect of SEVI on HIV virion entry into primary CD4 T cells was assessed with a virion-based HIV fusion assay (4).”
Self-citationProduction of Papillomavirus‐Based Gene Transfer Vectors
Buck, C. B., & Thompson, C. D. (2007) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb2601s37 · Cited by 173
Zhou, J., Yuan, X., Dismuke, D., Forshey, B. M., Lundquist, C., Lee, K.-H., Aiken, C., & Chen, C. H. (2004) · Journal of Virology · doi:10.1128/jvi.78.2.922-929.2004 · Cited by 176
“A similar assay has recently been reported (5).”
MethodNrf2 expression modifies influenza A entry and replication in nasal epithelial cells
Kesic, M. J., Simmons, S. O., Bauer, R., & Jaspers, I. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.04.027 · Cited by 164
“To dissect specific points in the virus life cycle that could determine the role Nrf2 gene expression plays in viral susceptibility and/or viral replication, which ultimately dictates viral pathogenesis and outcome, we developed an enzymatic virus-like particle assay that was adapted from previous studies using VLPs t…”
MethodHepatitis C Virus Glycoproteins Mediate Low pH-dependent Membrane Fusion with Liposomes
Lavillette, D., Bartosch, B., Nourrisson, D., Verney, G., Cosset, F., Pénin, F., & Pécheur, E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509747200 · Cited by 171
Tetherin Restricts Productive HIV-1 Cell-to-Cell Transmission
Casartelli, N., Sourisseau, M., Feldmann, J., Guivel-Benhassine, F., Mallet, A., Marcelin, A.-G., Guatelli, J., & Schwartz, O. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000955 · Cited by 157
“Our results indicate that tetherin impairs an early step of the viral cycle. We hypothesized that the fusion ability of the viral aggregates could be reduced. We adapted a cell-free virion-based assay”
ResultDirect Visualization of the Conformational Dynamics of Single Influenza Hemagglutinin Trimers
Das, D. K., Govindan, R., Nikić-Spiegel, I., Krammer, F., Lemke, E. A., & Munro, J. B. (2018) · Cell · doi:10.1016/j.cell.2018.05.050 · Cited by 159
Yonezawa, A., Cavrois, M., & Greene, W. C. (2005) · Journal of Virology · doi:10.1128/jvi.79.2.918-926.2005 · Cited by 163
“(HIV-1) virions to target cells was described (7).”
BackgroundSelf-citationRoan, N. R., Müller, J. A., Liu, H., Chu, S., Arnold, F., Stürzel, C. M., Walther, P., Dong, M., Witkowska, H. E., Kirchhoff, F., et al. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.10.010 · Cited by 164
“Virion fusion was performed similar to previously described methods (Cavrois et al., 2002).”
MethodResultSelf-citationVanCompernolle, S. E., Taylor, R. J., Oswald-Richter, K., Jiang, J., Youree, B. E., Bowie, J. H., Tyler, M. J., Conlon, J. M., Wade, D., Aiken, C., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.18.11598-11606.2005 · Cited by 163
“For this experiment, we employed a recently developed reporter assay to quantify HIV particle entry (13).”
MethodRecent advancements for the evaluation of anti-viral activities of natural products
Chattopadhyay, D., Sarkar, M. C., Chatterjee, T., Sharma Dey, R., Bag, P., Chakraborti, S., & Khan, M. T. H. (2009) · New Biotechnology · doi:10.1016/j.nbt.2009.03.007 · Cited by 153
IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity
Tartour, K., Appourchaux, R., Gaillard, J., Nguyen, X.-N., Durand, S., Turpin, J., Beaumont, E., Roch, E., Berger, G., Mahieux, R., et al. (2014) · Retrovirology · doi:10.1186/s12977-014-0103-y · Cited by 139
“As previously reported, all IFITMs were found at the plasma membrane, although more specific patterns could be observed for individual IFITMs (more prominent intracellular localization of Figure 3 IFITMs partly co-localize with HIV-1 Gag in virus-producing c the intracellular distribution of IFITMs and Gag, HEK293T ce…”
BackgroundMethodInfluentialDesigned proteins induce the formation of nanocage-containing extracellular vesicles
Votteler, J., Ogohara, C., Yi, S., Hsia, Y., Nattermann, U., Belnap, D. M., King, N. P., & Sundquist, W. I. (2016) · Nature · doi:10.1038/nature20607 · Cited by 153
Goujon, C., & Malim, M. H. (2010) · Journal of Virology · doi:10.1128/jvi.00854-10 · Cited by 135
“To assess effects on entry directly, we used the well-described BlaM-Vpr assay, where virus-associated -lactamase is transferred to the target cell cytosol following membrane fusion and is detected through enzymatic cleavage of a fluorescent substrate (18).”
MethodMulti-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance
Rabi, S. A., Laird, G. M., Durand, C. M., Laskey, S. B., Shan, L., Bailey, J. R., Chioma, S., Moore, R. D., & Siliciano, R. F. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67399 · Cited by 159
“Median effect plots illustrating the effects of the PIs ATV, DRV, and LPV on HIV-1 entry, reverse transcription, all postentry events, and overall infectivity.”
InfluentialProtein transduction from retroviral Gag precursors
Voelkel, C., Galla, M., Maetzig, T., Warlich, E., Kuehle, J., Zychlinski, D., Bode, J., Cantz, T., Schambach, A., & Baum, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914517107 · Cited by 137
HIV-1 Uncoating Is Facilitated by Dynein and Kinesin 1
Lukic, Z., Dharan, A., Fricke, T., Diaz-Griffero, F., & Campbell, E. M. (2014) · Journal of Virology · doi:10.1128/jvi.02219-14 · Cited by 130
“This effect was not due to a defect in fusion mediated by Noc, since the level of fusion of VSV-G-pseudotyped HIV-1 loaded with Vpr– -lactamase (27) was not reduced by Noc treatment.”
BackgroundKim, K.-A., Yolamanova, M., Zirafi, O., Roan, N. R., Ständker, L., Forssmann, W., Burgener, A., Dejucq‐Rainsford, N., Hahn, B. H., Shaw, G. M., et al. (2010) · Retrovirology · doi:10.1186/1742-4690-7-55 · Cited by 155
“Kim et al. Retrovirology 2010, 7:55 http://www.retrovirology.com/content/7/1/55 Page 6 of 12 try-based HIV-1 virion-fusion assay [ 35 ].”
Self-citationIn Vitro Derived Dendritic Cells trans-Infect CD4 T Cells Primarily with Surface-Bound HIV-1 Virions
Cavrois, M., Neidleman, J., Kreisberg, J. F., & Greene, W. C. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030004 · Cited by 141
“HIV-1 fusion to CD4þCD3þ cells was measured using the virion-based fusion assay combined with immunostaining with CD1a-APC, CD4-PE Cy7, and CD3-APC Cy7 antibodies [13,14].”
BackgroundMethodSelf-citationHIV-1 Induces the Formation of Stable Microtubules to Enhance Early Infection
Sabo, Y., Walsh, D., Barry, D., Tinaztepe, S., Santos, K. D. L., Goff, S. P., Gundersen, G. G., & Naghavi, M. H. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.10.012 · Cited by 141
“To test this, we used a previously described fusion assay in which HIV-1 cores containing a b-lactamase-Vpr fusion protein allow monitoring of viral penetration into the cytosol (Cavrois et al., 2002).”
MethodCampbell, E. M., Perez, O., Melar, M., & Hope, T. J. (2007) · Virology · doi:10.1016/j.virol.2006.10.025 · Cited by 136
“To date, the preferred method to induce incorporation of nonviral proteins into HIV virions has been the generation of fusion proteins tethered to the viral Vpr protein (Cavrois et al., 2002; McDonald et al., 2002; Sato et al., 1995; Wu et al., 1995).”
HIV-1 capsids bind and exploit the kinesin-1 adaptor FEZ1 for inward movement to the nucleus
Malikov, V., da Silva, E. S., Jovasevic, V., Bennett, G., de Souza Aranha Vieira, D. A., Schulte, B., Diaz-Griffero, F., Walsh, D., & Naghavi, M. H. (2015) · Nature Communications · doi:10.1038/ncomms7660 · Cited by 130
Systematic identification of synergistic drug pairs targeting HIV
Tan, X., Hu, L., Luquette, L. J., Gao, G., Liu, Y., Qu, H., Xi, R., Lu, Z. J., Park, P. J., & Elledge, S. J. (2012) · Nature Biotechnology · doi:10.1038/nbt.2391 · Cited by 131
Dale, B. M., McNerney, G. P., Thompson, D. L., Hubner, W., de los Reyes, K., Chuang, F. Y. S., Huser, T., & Chen, B. K. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.10.015 · Cited by 133
“Cell-Cell Transfer of HIV-1 Promotes Efficient Viral Fusion with Kinetics and Inhibitor Sensitivity that Are Distinct from Cell-free Virus To study the ability of HIV-1 particles to induce viral membrane fusion after internalization through the VS, we employed the Vpr-b-lactamase (Vpr-BlaM) enzymatic assay for measuri…”
MethodSato, K., Aoki, J., Misawa, N., Daikoku, E., Sano, K., Tanaka, Y., & Koyanagi, Y. (2008) · Journal of Virology · doi:10.1128/jvi.01044-07 · Cited by 122
“The HIV-1 fusion assay, which is based on the incorporation of -lactamase–Vpr chimeric proteins (BlaM-Vpr) into virions and subsequent BlaM cleavage of a fluorescent dye (CCF2) present in target cells, was performed as described previously (8).”
MethodInfluentialDouble-labelled HIV-1 particles for study of virus–cell interaction
Lampe, M., Briggs, J. A. G., Endress, T., Glass, B., Riegelsberger, S., Kräusslich, H.-G., Lamb, D. C., Bräuchle, C., & Müller, B. (2007) · Virology · doi:10.1016/j.virol.2006.10.005 · Cited by 125
“Enzymatically active BlaM is released into the cytoplasm upon fusion and can be quantitated by determining cleavage of the fluorescent substrate CCF2 (Cavrois et al., 2002; Münk et al., 2002).”
BackgroundInfluentialPrinciples of Virus Uncoating: Cues and the Snooker Ball
Yamauchi, Y., & Greber, U. F. (2016) · Traffic · doi:10.1111/tra.12387 · Cited by 134
“Beta-lactamase (BlaM) viral core chimeras, such as BlaM fused to HIV-1 viral protein R (vpr) can be used to detect virus uncoating with high sensitivity (168,169).”
MethodBalakrishnan, M., Yant, S. R., Tsai, L., O’Sullivan, C., Bam, R. A., Tsai, A., Niedziela-Majka, A., Stray, K. M., Sakowicz, R., & Cihlar, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074163 · Cited by 126
Barrero-Villar, M., Cabrero, J. R., Gordón-Alonso, M., Barroso-González, J., Álvarez-Losada, S., Muñoz-Fernández, M. A., Sánchez-Madrid, F., & Valenzuela-Fernández, A. (2009) · Journal of Cell Science · doi:10.1242/jcs.035873 · Cited by 121
“To exclude any influence of possible effects at late steps in the infection cycle, we infected cells with a single-cycle virus bearing either the reporter gene Luciferase (Luc-HIV-1) (Gummuluru et al., 2002) or the reporter enzyme β-lactamase (Blam-HIV-1) (Cavrois et al., 2002).”
BackgroundMethodKreisberg, J. F., Yonemoto, W., & Greene, W. C. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051856 · Cited by 123
“CCF2 substrate, with the former refl ecting fusion (24).”
BackgroundMethodInfluentialSelf-citationA Bioluminogenic Substrate for In Vivo Imaging of β‐Lactamase Activity
Yao, H., So, M., & Rao, J. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200701931 · Cited by 124
Souriant, S., Balboa, L., Dupont, M., Pingris, K., Kviatcovsky, D., Cougoule, C., Lastrucci, C., Bah, A., Gasser, R., Poincloux, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.091 · Cited by 133
“Although cell-surface expression of the HIV-1 entry receptors CD4, CCR5 and CXCR4 was increased in CmMTB-treated cells compared to control cells (Figure 4A), virus entry was unchanged in these cells, as shown using the BlaM-Vpr fusion assay (Cavrois et al., 2002) (Figure 4B).”
Moloney Leukemia Virus 10 (MOV10) Protein Inhibits Retrovirus Replication
Wang, X., Han, Y., Dang, Y., Fu, W., Zhou, T., Ptak, R. G., & Zheng, Y.-H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.109314 · Cited by 116
Brindley, M. A., Hunt, C. L., Kondratowicz, A. S., Bowman, J., Sinn, P. L., McCray, P. B., Quinn, K., Weller, M. L., Chiorini, J. A., & Maury, W. J. (2011) · Virology · doi:10.1016/j.virol.2011.04.002 · Cited by 133
“ZEBOV ΔO VLP fusion with endosomal membranes was measured by a change in fluorescence due to cleavage of the β-lactam ring (Cavrois et al., 2002; Cavrois et al., 2004).”
Constitutive resistance to viral infection in human CD141 + dendritic cells
Silvin, A., Yu, C. I., Lahaye, X., Imperatore, F., Brault, J.-B., Cardinaud, S., Becker, C., Kwan, W.-H., Conrad, C., Maurin, M., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai8071 · Cited by 114
Programmable Extracellular Vesicles for Macromolecule Delivery and Genome Modifications
Zhang, X., Xu, Q., Zi, Z., Liu, Z., Wan, C., Crisman, L., Shen, J., & Liu, X. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.11.007 · Cited by 111
Alvarez, Y., Tuen, M., Shen, G., Nawaz, F., Arthos, J. A., Wolff, M. J., Poles, M. A., & Hioe, C. E. (2013) · Journal of Virology · doi:10.1128/jvi.01838-13 · Cited by 140
“Virus entry was detected by cell staining with CCF2-AM (15).”
Geuenich, S., Goffinet, C., Venzke, S., Nolkemper, S., Baumann, I., Plinkert, P. K., Reichling, J., & Keppler, O. T. (2008) · Retrovirology · doi:10.1186/1742-4690-5-27 · Cited by 119
“cent CCF2 substrate, which is loaded into target cells, allows a sensitive detection of virus entry and can be quantified by flow cytometry [12].”
Schaeffer, E., Soros, V. B., & Greene, W. C. (2004) · Journal of Virology · doi:10.1128/jvi.78.3.1375-1383.2004 · Cited by 115
“To examine whether HIV-1 entry by fusion is increased in the presence of endosome inhibitors, we employed a virionbased fusion assay we recently described (7) that measures cytosolic delivery of BlaM from virions into target cells.”
BackgroundMethodInfluentialSelf-citationWei, B. L., Denton, P. W., O’Neill, E., Luo, T., Foster, J. L., & García, J. V. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5705-5712.2005 · Cited by 122
“(6) to show a near-15-fold difference in cytosolic BlaM-Vpr-positive cells between HIV-1NL4-3 and HIV-1SF2, strongly implicating a weak ability of HIV-1SF2 particles to fuse with cellular membranes as the major reason for the low infectivity of this virus.”
BackgroundMethodInfluentialHIV-1 Gag Processing Intermediates Trans-dominantly Interfere with HIV-1 Infectivity
Müller, B., Anders, M., Akiyama, H., Welsch, S., Glass, B., Nikovics, K., Clavel, F., Tervo, H.-M., Keppler, O. T., & Kräusslich, H.-G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.027144 · Cited by 106
Identification of preferential CD4+ T-cell targets for HIV infection in the cervix
Joag, V., McKinnon, L. R., Liu, J., Kidane, S., Yudin, M. H., Nyanga, B., Kimwaki, S., Besel, K., Obila, J. O., Huibner, S., et al. (2015) · Mucosal Immunology · doi:10.1038/mi.2015.28 · Cited by 114
“Nonetheless, Cavrois et al.(41) previously used a replication-competent BlaMVpr HIV provirus to demonstrate a direct correlation between HIV entry and de novo viral replication.”
MethodInfluentialKondo, N., Miyauchi, K., Meng, F., Iwamoto, A., & Matsuda, Z. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.067090 · Cited by 112
Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion
de la Vega, M., Marin, M., Kondo, N., Miyauchi, K., Kim, Y., Epand, R. F., Epand, R. M., & Melikyan, G. B. (2011) · Retrovirology · doi:10.1186/1742-4690-8-99 · Cited by 111
“Virus-cell fusion was examined using the b-lactamase (BlaM) assay, which measures the transfer of viral core-associated enzyme into the cytosol [32].”
Dharan, A., Opp, S., Abdel-Rahim, O., Keceli, S. K., Imam, S., Diaz-Griffero, F., & Campbell, E. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712033114 · Cited by 105
“Blam-Vpr Fusion Assay.”
MethodInfluentialClerc, I., Moussa, D. A., Vahlas, Z., Tardito, S., Oburoglu, L., Hope, T. J., Sitbon, M., Dardalhon, V., Mongellaz, C., & Taylor, N. N. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0084-1 · Cited by 121
Platt, E. J., Durnin, J. P., & Kabat, D. (2005) · Journal of Virology · doi:10.1128/jvi.79.7.4347-4356.2005 · Cited by 127
“As we discuss below, these results are quantitatively consistent with the rapid rate of HIV-1 endocytosis, which was previously proposed to cause virus inactivation (3, 17, 21, 34, 35, 48).”
BackgroundResultInfluentialRole of Abl Kinase and the Wave2 Signaling Complex in HIV-1 Entry at a Post-Hemifusion Step
Harmon, B., Campbell, N., & Ratner, L. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000956 · Cited by 108
“. In this assay siRNA expressing cells were mixed for 90 min with HIV-1 strains with cores carrying a β-lactamase (BlaM)-Vpr chimera, and pseudotyped with Env from ADA (R5), YU2 (R5) or HXB2 (X4), and fusion was quantified by measuring the cytosolic activity of viral core-associated BlaM”
MethodVorster, P. J., Guo, J., Yoder, A., Wang, W., Zheng, Y., Xu, X., Yu, D., Spear, M., & Wu, Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.182238 · Cited by 104
Dai, J., Agosto, L. M., Baytop, C., Yu, J. J., Pace, M. J., Liszewski, M. K., & O'Doherty, U. (2009) · Journal of Virology · doi:10.1128/jvi.01910-08 · Cited by 102
“The coreceptor levels were determined by surface staining in fluorescence-activated cell sorting (FACS) buffer (phosphate-buffered saline with 1% bovine serum albumin and 2 mM EDTA) and by blocking nonspecific binding with mouse immunoglobulin G.”
BackgroundMethodInfluentialSimmons, G., Rennekamp, A. J., Chai, N., Vandenberghe, L. H., Riley, J. L., & Bates, P. F. (2003) · Journal of Virology · doi:10.1128/jvi.77.24.13433-13438.2003 · Cited by 109
“Hydrolysis of a -lactam ring in CCF2 by Bla creates a product that, when excited at 409 nm, fluoresces at a lower emission wavelength of 460 nm (4, 19).”
BackgroundCharacterization of Restrictions to Human Immunodeficiency Virus Type 1 Infection of Monocytes
Triques, K., & Stevenson, M. (2004) · Journal of Virology · doi:10.1128/jvi.78.10.5523-5527.2004 · Cited by 98
“The extent of virus entry was examined as described elsewhere (1, 18).”
BackgroundMethodBlood-Derived CD4 T Cells Naturally Resist Pyroptosis during Abortive HIV-1 Infection
Muñoz-Arias, I., Doitsh, G., Yang, Z., Sowinski, S., Ruelas, D. S., & Greene, W. C. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.09.010 · Cited by 114
“Cells were washed with CO2-independent medium, stained with CCF2-AM for 1 h at room temperature, and incubated overnight in probenecid/CO2-independent medium at room temperature as described (Cavrois et al., 2002).”
InfluentialSelf-citationCeramide, a target for antiretroviral therapy
Finnegan, C. M., Rawat, S. S., Puri, A., Wang, J. M., Ruscetti, F. W., & Blumenthal, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402874101 · Cited by 104
Intracellular FRET-based probes: a review
Rowland, C. E., Brown, C. W., Medintz, I. L., & Delehanty, J. B. (2015) · Methods and Applications in Fluorescence · doi:10.1088/2050-6120/3/4/042006 · Cited by 109
“Another example in HIV research used FRET to demonstrate the association of CCR5/CD4 receptors on the plasma membrane with the glycoprotein gp120 to initiate viral entry into the cell.”
BackgroundMethodInfluentialKaushik, R., Zhu, X., Stranska, R., Wu, Y., & Stevenson, M. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2009.05.022 · Cited by 95
“We next examined the functionality of the p6 domain within the chimeric MLV gag protein by its ability to package a Vpr-β-lactamase fusion protein within virions (Cavrois et al., 2002).”
Backgroundα 5 β 1 -Integrin controls ebolavirus entry by regulating endosomal cathepsins
Schornberg, K. L., Shoemaker, C. J., Dube, D., Abshire, M. Y., Delos, S. E., Bouton, A. H., & White, J. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807578106 · Cited by 100
“Upon fusion, the BlaM is released into the cytoplasm where it can cleave a fluorogenic substrate, resulting in a shift in fluorescence that can be measured by flow cytometry (12).”
BackgroundPurinergic Receptors Are Required for HIV-1 Infection of Primary Human Macrophages
Hazleton, J. E., Berman, J. W., & Eugenin, E. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102482 · Cited by 92
The interferon-inducible isoform of NCOA7 inhibits endosome-mediated viral entry
Doyle, T., Moncorgé, O., Bonaventure, B., Pollpeter, D., Lussignol, M., Tauziet, M., Apolonia, L., Catanese, M. T., Goujon, C., & Malim, M. H. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0273-9 · Cited by 100
“pBlaM-Vpr and pAdVAntage have been described (30).”
Covalent Modification of Human Immunodeficiency Virus Type 1 p6 by SUMO-1
Gurer, C., Berthoux, L., & Luban, J. (2004) · Journal of Virology · doi:10.1128/jvi.79.2.910-917.2005 · Cited by 94
“Using an enzymatic assay in which a Vpr– -lactamase fusion is delivered into target cells (8), we determined that the block to infection was not at the entry step (data not shown).”
MethodWang, C. X., Sather, B. D., Wang, X., Adair, J., Khan, I., Singh, S., Lang, S., Adams, A., Curinga, G., Kiem, H.-P., et al. (2014) · Blood · doi:10.1182/blood-2013-12-546218 · Cited by 88
“Consistent with this idea, we observed increased cytoplasmic entry of LV cores following rapamycin treatment using a BLAM-Vpr fusion assay (Figure 5E).(40) Moreover, the amounts of LV reversetranscription products quantified by quantitative polymerase chain reaction (qPCR) were increased by a factor of 2 to 3, mirrori…”
MethodDas, D. K., Bulow, U. S., Diehl, W. E., Durham, N. D., Senjobe, F., Chandran, K., Luban, J., & Munro, J. B. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000626 · Cited by 93
“Cells were maintained in DMEM (Thermo Fisher, Waltham, MA) supplemented with 10% FBS (Gemini Bio, West Sacramento, CA), 100 U/mL penicillin/streptomycin (Thermo Fisher, Waltham, MA), and 2 mM L-glutamine (Thermo Fisher, Waltham, MA).”
MethodInfluentialTardif, M. R., & Tremblay, M. J. (2003) · Journal of Virology · doi:10.1128/jvi.77.22.12299-12309.2003 · Cited by 91
“, CD4 T lymphocytes) than isogenic viruses lacking host ICAM-1, we performed a recently developed enzyme-based fusion assay (5, 27).”
MethodNef Does Not Affect the Efficiency of Human Immunodeficiency Virus Type 1 Fusion with Target Cells
Tobiume, M., Lineberger, J. E., Lundquist, C. A., Miller, M. D., & Aiken, C. (2003) · Journal of Virology · doi:10.1128/jvi.77.19.10645-10650.2003 · Cited by 93
“Similar HIV-1 fusion assays have recently been reported (7, 36).”
Arnold, F., Schnell, J., Zirafi, O., Stürzel, C. M., Meier, C. A., Weil, T., Ständker, L., Forssmann, W., Roan, N. R., Greene, W. C., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06121-11 · Cited by 93
“Additionally, a virion fusion assay (2) revealed that the PAP85-120 fibrils enhanced HIV-1 fusion to CD4 T cells purified from the female genital mucosa (see the methods described in reference 13) (Fig.”
Self-citation
Metadata
- Authors
- Cavrois, M., de Noronha, C., & Greene, W. C.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Greene, Warner C.
- Venue
- Nature Biotechnology
- Published
- 2002-09-30
- Volume
- 20
- Issue
- 11
- Pages
- 1151-1154
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2029379203
- Cited by
- 475
- References
- 16
- Citations by year
- 2026: 13 · 2025: 11 · 2024: 12 · 2023: 9 · 2022: 19 · 2021: 24 · 2020: 22 · 2019: 25 · 2018: 20 · 2017: 31 · 2016: 16 · 2015: 27 · 2014: 28 · 2013: 22 · 2012: 31
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P01 HD40543, P01HD040543)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1, viral entry, fluorescent substrate, HIV-1 envelope
- MeSH terms
- Cell Fusion, Humans, Immunoenzyme Techniques, Membrane Fusion, Sensitivity and Specificity, T-Lymphocytes, Tumor Cells, Cultured, Viral Fusion Proteins, Virion, Reproducibility of Results, HIV-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.